EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses

Yu Guo, Meng Wang, Yujing Xuan, Lvla Pan, Wenyi Yan, Jisiyu Cheng, Yang Yu, Xiangyu Wang, Lihua Xu, Xianlei Sun, Ruxia Han, Lingling Si und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2026-016326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yu Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Met…. Hauptthemen laut MEDLINE: Vaccinia virus, Oncolytic Viruses, Interleukin-23, Pancreatic Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Central Plains Science and Technology Innovation Leading Talents, the National Key Research and Development Program of China, Joint Fund for Science and Technology Research and Development of Henan province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Oncolytic viruses represent a promising immunotherapeutic strategy for converting pancreatic and other immunologically cold tumors. While their ability to stimulate innate immune signaling and promote antitumor immunity is established, mechanisms enabling durable adaptive responses remain poorly defined. METHODS: We used CRISPR-Cas9-based homologous recombination to generate a thymidine kinase (TK) and B2R double-deleted backbone virus, VV∆TK∆B2R (VV-DD). On this backbone, we engineered VV∆TKmp40∆B2Rmp19 (VV-DDIL23), which expresses the p40 and p19 subunits of interleukin-23 (IL-23) separately to mimic natural heterodimer assembly. Its antitumor efficacy was evaluated in immunosuppressive pancreatic ductal adenocarcinoma models and compared with a single-chain IL-23 fusion construct (VV-DDIL23F). In parallel, unbiased single-cell RNA sequencing was employed to systematically dissect the immune mechanisms underlying the potent antitumor activity of VV-DDIL23. RESULTS: VV-DDIL23 exhibited potent antitumor efficacy and significantly outperformed VV-DDIL23F. Single-cell RNA sequencing revealed that VV-DDIL23 enhanced antigen processing and presentation in macrophages, characterized by elevated major histocompatibility complex-II expression, upregulation of co-stimulatory molecules, and production of cytokines including interferon-I and IL-1β. This was accompanied by the emergence of a distinct population of tumor-infiltrating CD4+ T cells that mediated long-term memory immune surveillance against tumors. Mechanistically, VV-DDIL23 infection triggered tumor cell-mediated activation of the macrophage inflammasome, leading to IL-1β release. Notably, IL-1β synergized with virally encoded IL-23 to promote the differentiation of Th17-skewed Cxcr6+Rora+ CD4+ T cells with sustained antitumor functions. CONCLUSION: This work reveals a previously unrecognized pathway linking innate viral recognition by macrophages to CD4+ T cell-directed differentiation and tumor clearance, providing a novel therapeutic strategy to overcome immunosuppression in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccinia virusOncolytic VirusesInterleukin-23Pancreatic NeoplasmsInflammasomesTh17 CellsOncolytic VirotherapyCD4-Positive T-LymphocytesCarcinoma, Pancreatic DuctalAnimalsHumansMiceFemaleCell Line, Tumor

Stichwörter der Autor:innen

Gene therapyImmunotherapyIntratumoralOncolytic virus

Substanzen

Interleukin-23Inflammasomes

Autor:innen und Institutionen

  • Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer…
  • Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, University of Chinese Academy of Sciences, Sh…
  • Henan Red Cross Blood Centre, Zhengzhou, China.
  • Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.

Förderung

  • the Central Plains Science and Technology Innovation Leading Talents
  • the National Key Research and Development Program of China
  • Joint Fund for Science and Technology Research and Development of Henan province
  • the National Natural Science Foundation of China
  • the Shanghai Pujiang Program
  • the Strategic Priority Research Program of the Chinese Academy of Science
  • the Natural Science Foundation of Henan Province for Distinguished Young Scholars

Zitieren

APA

Guo, Y., Wang, M., Xuan, Y., Pan, L., Yan, W., Cheng, J., Yu, Y., Wang, X., Xu, L., Sun, X., Han, R., Si, L., Wang, Y., Li, S., & Wang, P. (2026). IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-016326

Vancouver

Guo Y, Wang M, Xuan Y, Pan L, Yan W, Cheng J, et al. IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-016326

BibTeX
@article{Guo2026,
  author = {Guo, Yu and Wang, Meng and Xuan, Yujing and Pan, Lvla and Yan, Wenyi and Cheng, Jisiyu and Yu, Yang and Wang, Xiangyu and Xu, Lihua and Sun, Xianlei and Han, Ruxia and Si, Lingling and Wang, Yaohe and Li, Sirui and Wang, Pengju},
  title = {IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2026-016326}
}
Kostenlos starten →